Precigen returns to profit in Q2 FY26; revenue rises to $54.98 million
PGEN•Product revenue rises on Papzimeos sales
Product revenue rose to $53.26 million, reflecting Papzimeos commercial sales following FDA approval in August 2025.
SG&A expense increased 37.9% to $22.25 million, driven by Papzimeos commercialization activities.
Precigen swings to profit as revenue jumps
Precigen swung to net income of $20.07 million on revenue of $54.98 million in Q2 2026, from a net loss of $26.64 million on revenue of $856,000.
Operating income was $22.64 million, versus an operating loss of $31.76 million.
